Partnership with Merck

Pierre Fabre Médicament et Merck & Co signed an agreement in August 2004 for a joint research program over 3 years to develop the project F50035 which is a humanized antibody discovered by CIPF, targeting the type 1 (IGF-1R) insulin-like growth factor receptor. 


Merck licensed this antibody and the program for cancer treatment is currently in phase II.